



# MSTS Newsletter

Volume 321, Fall 2023

## Inside this Issue

President's Report . . . . .1	SarcomaStrong Corner . . . . .3	Education Committee . . . . .10
Annual Meeting-Program at a Glance . . .2	Thank You MSTS Donors! . . . . .4	Save the Date - 2024 Annual Meeting .10
MSTS Executive Committee . . . . .2	Thank You MSTS Sponsors! . . . . .5	Membership Committee . . . . .12
Save the Date - Specialty Day 2024 . . . .3	SarcomaStrong Corner (cont'd) . . . . 6,8	Musculoskeletal Tumor Registry . . . . .14
	Practice Management Committee. . . .10	Guidelines and EBM Committee . . . . .14

## President's Report – Michelle Ghert, MD, FRCSC



Michelle Ghert, MD, FRCSC

Dear MSTS Members,

Welcome back to Canada for the first time in over 20 years! The 2023 Annual Meeting is being held at the iconic Fairmont Banff

Springs Hotel. Rocky Mountain peaks, turquoise glacial lakes, and adventure come together in Banff National Park - Canada's first national park and the flagship of the nation's park system. Banff is part of the Canadian Rocky Mountain Parks UNESCO World Heritage Site and is a short drive away from other world-famous attractions including Moraine Lake and Lake Louise.

The Program Committee has assembled a fantastic agenda, beginning with Wednesday's MORI Young Members meeting. At the Opening Ceremony immediately before the welcome reception on Wednesday evening, we are excited to present our "Welcome to Canada" guest speaker for the opening ceremony, bestselling author, and modern-day explorer Adam Shoalts. Expect to be regaled with tales of his exploration of Canada's most remote areas, including his 4000 km solo journey across Canada's arctic. Our Presidential

Guest Speaker on Friday will be Dr. Gordon Guyatt, the father of "evidence-based medicine" and a member of the Canadian Medical Hall of Fame.

As a first for the MSTS, the scientific sessions will take place over a full 2 days and will feature 76 podium presentations on a broad range of topics including bone and soft tissue sarcomas, metastatic bone disease, novel treatment techniques, immunotherapy and immunomodulation. MSTS has gone paperless! A total of 159 e-posters will be featured in the reception hall and will be available on the new Chime Meeting App, on which you can also personalize your agenda, view podium abstracts, and learn more about our sponsors. Finally, 3 special sessions will highlight the current status of musculoskeletal oncology care in our international member countries, the Sarcoma Strong Research Update, and Collaborative Clinical Studies.

The gala dinner on Thursday night will be held at Mount View BBQ featuring spectacular views of the Rocky Mountains, delicious local cuisine, and line dance lessons with local musicians. For the fitness enthusiasts, we have reintroduced the 5k Fun Run on Friday morning with free MSTS branded water bottles provided to finishers – fast or slow!

We are excited to have sold out sponsorship for this year's meeting. Please recognize all our sponsors by visiting their exhibits and attending the 4 featured Product Theater presentations. We simply cannot run a successful meeting without their support.

A special thank you to Meeting Co-Chairs Dr. Peter Ferguson and Dr. Jay Wunder, local host Dr. Joe Kendal, social organizer Melinda Ferguson, the entire Program Committee, and of course, our tireless executive team, Kerri Mink, and Deborah Meyer for organizing this "back to Canada" meeting at the Castle in the Rockies!

Finally, I would like to thank all members for the Executive Committee (Mike Mott, Carol Morris Ben Miller, Rajiv Rajani, Francis Lee, Matt DiCaprio, Kurt Weiss, Wakenda Tyler, Melissa Zimel, David Greenberg, Adam Levin, Tae Won Kim, Nick Tedesco, Raffi Avedian, Odion Binitie and Felafsa Wodajo), who have made my year as President an absolute joy. I am humbled by their tireless and brilliant volunteer work that continues to move MSTS forward as THE premier orthopedic oncology society.

Thank you!

**MSTS Headquarters**  
Schaumburg, IL 60173

1515 E. Woodfield Road, Suite 345

info@msts.org

847/698-1625


# 2023 Annual Meeting - Program At a Glance

## Wednesday, October 4th

12:00 PM – 7:00 PM	Registration	Van Horne Foyer
1:00 PM – 4:00 PM	MORI/MSTS Young Member Session	Van Horne Ballroom A&B
1:00 PM – 6:00 PM	Exhibit Booth Set Up	President's Hall
5:30 PM – 7:30 PM	Opening Session/Welcome Reception	Van Horne Foyer

## Thursday, October 5th

6:30 AM – 4:30 PM	Registration	Van Horne Foyer
7:00 AM – 4:30 PM	MSTS Exhibits	President's Hall
7:00 AM – 8:00 AM	Breakfast	President's Hall
7:00 AM – 4:30 PM	E-Posters on Display	Van Horne Foyer
8:00 AM – 8:10 AM	Introduction and Welcome	Van Horne Ballroom A&B
8:10 AM – 8:45 AM	SESSION I – Endoprosthetic Reconstruction	Van Horne Ballroom A&B
8:45 AM – 9:20 AM	SESSION II – Thrombosis and Thromboprophylaxis	Van Horne Ballroom A&B
9:25 AM – 9:55 AM	Break	President's Hall
9:25 AM – 9:55 AM	E-Poster Viewing	Van Horne Foyer
9:25 AM – 9:45 AM	Product Theater – Onkos Surgical (no CME credit)	Theater – Level I
9:55 AM – 10:30 AM	SESSION III – Benign Bone and Soft Tissue Tumors	Van Horne Ballroom A&B
10:30 AM – 11:15 AM	SESSION IV – Infection	Van Horne Ballroom A&B
11:15 AM – 11:45 AM	Break	President's Hall
11:15 AM – 11:45 AM	E-Poster Viewing	Van Horne Foyer
11:15 AM – 11:35 AM	Product Theater – Medtronic (no CME credit)	Theater – Level I
11:45 AM – 12:20 PM	SESSION V – Practice Patterns	Van Horne Ballroom A&B
12:20 PM – 1:00 PM	Lunch	President's Hall



**2023 ANNUAL MEETING**  
**October 4–6, 2023**

Fairmont Banff Springs Hotel  
Banff, Alberta, Canada

*Continued on page 3*



## MSTS Executive Committee

### President

Michelle Ghert, MD, FRCSC  
ghertm@mcmaster.ca

### President-Elect

Benjamin Miller, MD  
benjamin-j-miller@uiowa.edu

### Secretary

Rajiv Rajani, MD  
rrajani@ttuhsc.edu

### Treasurer

Francis Y. Lee, MD, PhD  
francis.lee@yale.edu

### Immediate Past President

Michael P. Mott, MD  
mmott2@hfhs.org

### Past President

Carol D. Morris, MD  
morrisc@mskcc.org

### Education Committee

Wakenda K. Tyler, MD  
wkt2106@cumc.columbia.edu

### Research Committee

Kurt Weiss, MD  
weiskr@upmc.edu

### Membership Committee

Matthew R. DiCaprio MD  
mdicaprio15@gmail.com

### Members-at-Large

David D. Greenberg, MD  
david.greenberg@health.slu.edu

Melissa Zimel, MD  
melissa.zimel@ucsf.edu

Registration is now open for the 2024 AAOS-MSTS Specialty Day on Friday, February 16th, from 8:00am to 3:00pm, at the Moscone Center in San Francisco. The Program Committee members, Luke Nystrom, Panos Papagelopoulos, and Melissa Zimel, have invited a diverse group of speakers guaranteed to be both educational and inspiring.

We will start the day featuring our Sarcoma Strong Research Grant recipients and explore other collaborative opportunities. The late morning session will highlight successes and failures of percutaneous and open pelvis reconstruction. Following the Business Meeting, we will have a multi-disciplinary session on caring for patients with metastatic disease, with experts from radiation oncology, interventional radiology, palliative and interventional pain management. Our Keynote Speaker, Dr. Michael Rabow, Professor of Clinical Medicine and Director of the Palliative Care Program at UCSF, will share his insights on "Caring for the Caregiver." The afternoon will dive into Practice Management with our own leaders discussing billing and coding, negotiations, lawsuits, being an expert witness, and industry consulting. Lastly, we will end the day with MSTS Gives Back, discussing patient advocacy, global surgery, philanthropy, and mentorship/orthopedic pipeline programs. We can't wait to see you all in San Francisco!



### Thursday, October 5th, continued

12:20 PM – 1:00 PM	E-Poster Viewing	Van Horne Foyer
1:00 PM – 2:10 PM	MSTS Business Meeting	Van Horne Ballroom A&B
2:10 PM – 2:30 PM	International Speakers	Van Horne Ballroom A&B
2:30 PM – 2:40 PM	Sarcoma Strong Funded Research Update	Van Horne Ballroom A&B
2:40 PM – 2:55 PM	Collaborative Prospective MSTS Research	Van Horne Ballroom A&B
2:55 PM – 3:05 PM	Panel Discussion	Van Horne Ballroom A&B
3:05 PM – 3:40 PM	SESSION VI – Patient Reported Outcomes, Surveillance and Staging	Van Horne Ballroom A&B
3:45 PM – 4:15 PM	Break	President's Hall
3:45 PM – 4:15 PM	E-Poster Viewing	Van Horne Foyer
3:45 PM – 4:05 PM	Product Theater – Zimmer Biomet (no CME credit)	Theater – Level I
4:15 PM – 5:00 PM	SESSION VII – Metastatic Bone Disease I	Van Horne Ballroom A&B
5:00 PM	Meeting Adjourns	
6:30 PM – 10:30 PM	MSTS Social Event – Mount View BBQ	

Starting at 5:45 PM, then every 30 minutes until everyone is picked up

Buses will begin leaving the venue at 9:00 PM with the final departure at 11:00 PM



### SarcomaStrong Corner – Matthew R. DiCaprio, MD

Sarcoma Strong Inc. has seen tremendous growth throughout 2023. None more evident than our passionate members starting or continuing to hold local events for their local sarcoma communities. A special recognition for Megan Anderson, and Alexandra Callan for an outstanding job achieving such high levels of sponsorship for their local events. The year started with a new venture for Sarcoma Strong, our inaugural annual dinner gala. With this jump start in fundraising we had a feeling 2023 would be a magical year. We far exceeded our fundraising goals through collaboration and belief in the mission.

Our signature, Global 5k Run/Walk event took place August 11-13th. We had a number of in person events before, after and during this weekend of global engagement.

July 29th El Paso, Texas  
led by Shaine Munoz and Rajiv Rajani

July 30th Syracuse, NY  
led by Rebecca Dorn

August 6th, Hamilton, Ontario  
led by Michelle Ghert and Serena Uppal

Continued on page 6

**Friday, October 6th**

6:30 AM – 8:30 AM	Registration	Van Horne Foyer
7:00 AM – 2:00 PM	MSTS Exhibits	President's Hall
7:00 AM – 8:00 AM	Breakfast	President's Hall
7:00 AM – 4:15 PM	E-Poster Viewing	Van Horne Foyer
8:00 AM – 8:05 AM	Announcements	Van Horne Ballroom A&B
8:05 AM – 8:40 AM	SESSION VIII – Bone Sarcoma I	
8:40 AM – 9:40 AM	Presidential Guest Speaker – Gordon Guyatt, MD, FRCP(C) OC Past and Future of Evidence -Based Medicine	
9:50 AM – 10:20 AM	Break	President's Hall
9:50 AM – 10:20 AM	E-Poster Viewing	Van Horne Foyer
9:50 AM – 10:10 AM	Product Theater – Stryker (no CME credit)	Theater – Level I
10:20 AM – 11:10 AM	SESSION IX – Soft-Tissue Sarcoma	Van Horne Ballroom A&B
11:10 AM – 11:45 AM	SESSION X – Novel Techniques	
11:45 AM – 12:45 PM	Lunch	President's Hall
11:45 AM – 12:45 PM	E-Poster Viewing	Van Horne Foyer
12:45 PM – 1:20 PM	SESSION XI – Immunotherapy and Immunomodulation	Van Horne Ballroom A&B
1:25 PM – 1:55 PM	Break	President's Hall
1:25 PM – 1:55 PM	E-Poster Viewing	Van Horne Foyer
1:25 PM – 1:45 PM	Final Opportunity to visit the Exhibit Hall and view the E-Posters!	Theater – Level I
1:55 PM – 2:30 PM	SESSION XII – Bone Sarcoma II	Van Horne Ballroom A&B
2:30 PM – 3:05 PM	SESSION XIII – Metastatic Bone Disease II	Van Horne Ballroom A&B
3:05 PM – 3:40 PM	SESSION XIV – Epidemiology and Outcomes Prediction	Van Horne Ballroom A&B
3:40 PM – 4:00 PM	Award Presentations	Van Horne Ballroom A&B
4:00 PM – 4:15 PM	Closing Remarks	Van Horne Ballroom A&B
4:15 PM	Meeting Adjourns	Van Horne Ballroom A&B

## Thank You Donors

Thank you to the following MSTS Donors


*Donations to MSTS January 1, 2023 through September 22, 2023*

- John H. Alexander, MD
- Edward Athanasian, MD
- Nicholas Bernthal, MD
- Odion Binitie, MD
- Gary Bos, MD
- Scot Brown, MD
- Emily Carmody, MD
- Felix Cheung, MD
- Kenneth Chirba, MD
- Matthew Colman, MD
- Gary E. Friedlaender, MD
- Mark C. Gebhardt, MD
- Michelle Ghert, MD, FRCS
- Steven Gitelis, MD
- Derek Hansen, MD
- John H. Healey, MD, FACS
- David Hennessey, MD
- Brandon Jonard, MD
- Bennie Lindeque, MD
- Susan McDowell, MD
- Carol Morris, MD, MS
- Michael Mott, MD
- Vincent Ng, MD
- Lukas M. Nystrom, MD
- Mary O'Connor, MD
- Richard O'Donnell, MD
- Rajiv Rajani, MD
- William G. Ward, MD, FACS
- Rosanna Wustrack, MD
- Melissa Zimel, MD

## Become a MSTS Member

Membership Application  
Deadline:  
**January 12, 2024**

Details [here](#).



# MSTS 2023 ANNUAL MEETING ACKNOWLEDGMENTS

## THANK YOU

The Musculoskeletal Tumor Society extends sincere appreciation to the following exhibitors for their generous support of the MSTS 2023 Annual Meeting.



### DIAMOND SPONSORS



**Medtronic**



**stryker**

### SPONSORS

3D Side  
Acera Surgical  
AAOS/MsTR Registry  
Biocomposites  
Carbofix Orthopedics, Inc.  
Deciphera Pharmaceuticals  
IlluminOss Medical, Inc.  
Implantcast North America

Inhibrx  
Insight Surgery  
Integrum, Inc.  
Link  
Merete Technologies, Inc.  
MTF Biologics  
OsteoCentric Technologies  
Signature Orthopaedics – USA  
Vector Surgical



Raise Sarcoma Awareness  
Advocate for Sarcoma Families  
Raise funds for Research



Our top finishers in 2023 receiving their medals.

August 12th, San Francisco, CA  
led by Rosanna Wustrack and Melissa Zimel

August 12th, Boston, MA  
led by Megan Anderson & Dipak Ramkumar

August 12th, Pennsauken, NJ  
led by Christina Gutowski and Tae Won Kim

August 13th, Saratoga Springs, NY  
led by Sarcoma Strong Inc


September 17th, Dallas, Texas  
led by Alexandra Callan

Several other more intimate events were held in several locations, including Detroit, MI, Akron, OH, and Jackson, MS. Sarcoma Strong would also like to acknowledge the Ohio Orthopaedic Oncologists who have collectively pledged and given to support sarcoma research within our society.

Composing this update in mid-September we have surpassed >\$200,000 funds raised in 2023, with more than 3 months until we close out our books for the year. This type of growth from other institutions will allow us to continue to fund quality, impactful sarcoma research projects for years to come. Our collaboration with MSTs began in 2015 and we anticipate by mid 2024 we will have supported \$1,000,000 in sarcoma research funding. It has been an amazing journey over the last 10 years, and we are proud of the impact we are having for the sarcoma community.

Working with Kurt Weiss, current research committee chair, and stirred by his leadership we are planning on announcing new exciting funding levels for 2024 Sarcoma Strong research grants.

In Upstate New York, we are busy planning our 2nd Annual Dinner Gala, set for March 2, 2024 at Glen Sanders Mansion in Scotia, New York. We hope to build from last year's success, attract new philanthropist to support our mission, and highlight our Sarcoma Strong service-learning students from Albany Medical College and the patients they advocate for. We are primed for further growth in 2024, having implemented a fully functional board of directors and established Sarcoma Strong Inc. as a 501c3 organization in 2023. We



Madison Dwyer (Sarcoma Strong service-learning president), Dr. Patrick DiCaprio, Congressman Paul Tonko NY-20 (left to right)

hope our efforts inspire you to want to host or lead an event at your institution or community.

Our 2024 Global Sarcoma Strong 5k Run/Walk event has been set for August 9-11, 2024. Registration will be opening after the new year. If you are interested in being more engaged or hosting a live or virtual event at your institution, please

*Continued on page 8*





# Global Modular Replacement System

One system, one vision, one solution

- Incorporates decades of experience with the Kinematic Rotating Hinge (KRH), Modular Replacement System (MRS) and Modular Rotating Hinge (MRH)
- Designed to help retain the quality of life for patients who require radical bone resection for proximal femur, distal femur, total femur and proximal tibia
- Offers various options of lengths, materials and fixation in stemmed configurations to help surgeons meet patients' needs

A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.

The information presented is intended to demonstrate the breadth of Stryker's product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker's products. The products depicted are CE marked according to the Medical Device Directive 93/42/EEC. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of Stryker's products in your area.

Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: GMRS, Stryker. All other trademarks are trademarks of their respective owners or holders.

contact me by cell 518-378-6499 or [dicaprm@amc.edu](mailto:dicaprm@amc.edu)

**Together We Unite  
the Sarcoma Fight**

Another easy way to support our fund-raising mission is to visit and share our merchandise shop with your local Sarcoma Community at [sarcomastrong.com/shop](http://sarcomastrong.com/shop) and purchase some SarcomaStrong swag.



*Team Kyle coming in strong and leading the effort in Saratoga Springs. Kyle Stickles (front center on one knee) is an osteosarcoma warrior and our honoree for 2023.*

# Delivering **Comprehensive Solutions** for **Significant Bone Loss**

**VISIT OUR BOOTH AT THE MSTs 2023  
ANNUAL MEETING TO LEARN MORE**

**DISCOVER OUR  
LIMB SALVAGE  
SOLUTIONS**



**ZIMMER BIOMET**

This material is intended for health care professionals. All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet. Distribution to any other recipient is prohibited. For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert and [www.zimmerbiomet.com](http://www.zimmerbiomet.com). Check for country product clearances and reference product specific instructions for use. ©2023 Zimmer Biomet • A0087.1-GLBL-en-Issue Date-2023-08

## Practice Management Committee – Adam Levin, MD, Chair

Greetings from the Practice Management Committee. This is always a busy time of year – recent fellowship graduates are entering their clinical practices, recognizing the complexities of starting a practice and building a network. As we continue to work through the changes in Evaluation and Management coding that came about in 2021, we have been partnering with other organizations to help clarify some of the apparent coding inconsistencies that have resulted. These efforts, as well as additional input and feedback through CPT, are ongoing in order to ensure optimal coding practices. Our committee has been following developments with CPT and NCCI, and we are closely monitoring the CMS Proposed Rule for 2024 as well as proposed legislative actions that may greatly impact clinical care and reimbursement.

Our committee's interests have largely focused upon practice organization and

management, expense reduction, coding integrity, reimbursement and compensation benchmarking, and access to care. In an attempt to provide more meaningful information and resources to the MSTs membership at large, the Practice Management committee has been brainstorming ideas. We have identified three overlying topics of focus, and we are requesting your assistance in helping us understand how to prioritize these in order to maximize the benefit to our membership.

1. Develop tools/guide to best to handle prior authorizations/denials
2. Identifying factors to consider when transitioning your practice, i.e. private practice to hospital employed, academic practice to private, etc.
3. Developing an accessible and expanding database of appropriate codes for our most utilized oncologic procedures in order to maximize reimbursement.



Please take a minute to fill out the survey and select the area that will most benefit you. Your help in this area will greatly help us and more importantly help the society at large. Please take a minute to fill out the survey and select the area that will most benefit you.

I want to also take this opportunity to thank the Practice Management Committee members for their outstanding dedication and hard work to serve our society.

## Education Committee Update – by Wakenda Tyler, MD

We have had a whirlwind of exciting things happening on the education side of the musculoskeletal tumor society. We had a plethora of outstanding ICL submissions from the membership with 5 being selected for AAOS in 2024. We have been supporting the Annual Meeting Committee for the annual meeting now just a few weeks away and the program is going to be outstanding. Keep a look out for some upcoming announcements about virtual webinars this winter and early spring.

We hope to keep providing educational opportunities throughout the year for our membership. As always, feel free to make suggestions about educational topics you think would be important to the membership as we can always try to incorporate that into the agenda for next year.

SAVE THE DATE

MUSCULOSKELETAL  
MSTs  
EST. 1977  
TUMOR SOCIETY

2024  
ANNUAL MEETING

September 11-13, 2024  
Sheraton Grand Riverwalk, Chicago, IL

The graphic features a cityscape background with a river and a bridge. The MSTs logo is prominently displayed in the center. The text 'SAVE THE DATE' is at the top, and '2024 ANNUAL MEETING' is in large green letters. The dates and location are at the bottom.



Introducing...

# The Juvenile Tumor System from Onkos Surgical®

**An extendible implant that allows for noninvasive bone lengthening in children following lower limb-sparing surgery**



**The leading 510(k) cleared solution** in the U.S. for noninvasive lengthening of a pediatric limb reconstruction device



**Designed to grow** with the child and stay with them throughout their adult life



**Helps reduce the risk of surgical complications** associated with limb reconstruction in pediatric cancer patients



**Over 1,100 JTS devices** have been implanted worldwide

Visit us in the MSTS Exhibit Hall.

**2023 MSTS Diamond Supporter**

Contact us to learn more:

973.264.5400 | [onkossurgical.com](https://onkossurgical.com)

Disclaimer: A surgeon should rely exclusively on his or her own professional medical/clinical judgment when deciding which particular product to use when treating a patient. ONKOS SURGICAL does not prescribe medical advice and advocates that surgeons be trained in the use of any particular product before using it in surgery. A surgeon must always refer to the product label and/or instructions for use before using any ONKOS SURGICAL product.

ONKOS SURGICAL, ELEOS, BioGrip, My3D, and GenVie are all registered marks and trademarks of Onkos Surgical. © 2023 ONKOS SURGICAL. All rights reserved. CORP 08.8.23 v0

## Precision Orthopaedics

- ELEOS™ Limb Salvage Solutions
- My3D® Personalized Solutions
- GenVie® Regenerative Biologics



## Membership Committee – Matthew R. DiCaprio, MD, Chair

The membership committee has worked to put together proposed modifications to the membership bylaws that was sent to each member by email on September 6th. We hope you can review the changes before our annual meeting as there will be a vote during the Business meeting in Banff. These changes are proposed to help handle some specific questions from applicants regarding which category of membership is most fitting for their experience and expertise. Our goal is to keep our membership strong and to attract the best and the brightest to our society. We wanted to make sure we were not inadvertently turning potential members away because of wording of our membership requirement bylaws. Thank you to our dedicated committee members: Christina Gutowski, Andre Spiguel, Vincent Ng, Kevin MacDonald, and Francis Hornicek, for their work on these bylaws changes, reviewing applications for membership, and for vetting proposed surveys to our members.

We want to encourage applications for membership at all levels: from residents, candidates, to active members. For those candidate members who are eligible for active membership please consider submitting an application with our next cycle in the new year. In recent years this has also surfaced as an area of confusion for current candidate members. We would like to have candidate members think of the process as a rolling one in which after candidate membership is attained the member will re-apply for active membership once all requirements are reached. These mainly include ABOS board

certification and having two letters of recommendation from society members. We will work on communicating this information to all current candidate members, especially those who are approaching or are past their “time limit” of 5 years as a candidate member.

We need each members assistance with efforts to diversify our society with other thought leaders in the musculoskeletal oncology space. We have very few affiliate members from other fields of medicine and would like to see that change in the future. Within your local multi-disciplinary teams at your institutions please consider inviting a member of your team; an oncologist, radiologist and or pathologist to an upcoming meeting to expose them to our great society and try to expand our collaboration to other physicians passionate about the care of musculoskeletal tumors. We continue to work with the communications committee to update the MSTS website with useful member information.

If you have any suggestions pertaining to membership, please feel free to contact me at [dicaprm@amc.edu](mailto:dicaprm@amc.edu).

Join us at the MSTS Business meeting in Banff to welcome our new members to the society!

If you are interested in becoming a member, or to change your current MSTS membership category, please click here to apply. The application deadline to be included in the next review is February, 2024. [View more online](#). Deadline is January 2024.

the power of registry

# DATA

## UNCOVER THE POWER OF DATA THROUGH THE MUSCULOSKELETAL TUMOR REGISTRY (MsTR)

Now is the time to join MsTR to take full advantage of the Power of Registry Data, which includes how you can:

- Access your data through the RegistryInsights® platform where you'll be able to harness national benchmarks through personalized data dashboards
- Use registry data to satisfy many of the quality requirements that you already are participating in
- Uncover greater insights to improve the quality of care you provide
- Read and digest all the new data reports that are regularly published and distributed

Uncover the Power of Data, contact us at [RegistryEngagement@aaos.org](mailto:RegistryEngagement@aaos.org) or visit [aaos.org/registries](http://aaos.org/registries)



## Come visit the MsTR Booth for more information and a demo



## Rethink desmoid tumors

Don't underestimate these unpredictable tumors and their "tendrillike" growths<sup>1</sup>

- Desmoid tumors can be locally invasive and painful, with **"tendrillike" growths that can threaten vital structures and compromise patients' function and quality of life**<sup>2-4</sup>
- Approximately **30% to 40% of desmoid tumors are initially misdiagnosed** due to their rarity and histologic mimics<sup>1</sup>
- There are currently **no FDA-approved treatment options** specifically indicated for desmoid tumors. **In most cases, surgery is no longer the recommended first-line treatment approach for desmoid tumors**<sup>1,5</sup>

A diagnosis can raise more questions for patients than answers. SpringWorks Therapeutics is committed to helping you provide resources and information for your patients with desmoid tumors.

Visit [DesmoidTumors.com/HCP](https://DesmoidTumors.com/HCP) for information and resources to diagnose, manage, and help guide patients with desmoid tumors.

### References

1. Kasper B, Baumgarten C, Garcia J, et al. Desmoid Working Group. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). *Ann Oncol.* 2017;28(10):2399-2408. 2. Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. *Curr Opin Oncol.* 2017;29(4):268-274. 3. Baranov E, Hornick JL. Soft tissue special issue: fibroblastic and myofibroblastic neoplasms of the head and neck. *Head Neck Pathol.* 2020;14(1):43-58. 4. Husson O, Younger E, Dunlop A, et al. Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care? *Support Care Cancer.* 2019;27(3):965-980. 5. The Desmoid Tumor Working Group. The management of desmoid tumors: a joint global evidence-based consensus guideline approach for adult and pediatric patients. Accessed April 10, 2022. [https://dtrf.org/wp-content/uploads/2020/02/Desmoid\\_Paper\\_2018\\_A4\\_RL\\_Web300-1.pdf](https://dtrf.org/wp-content/uploads/2020/02/Desmoid_Paper_2018_A4_RL_Web300-1.pdf).



# Musculoskeletal Tumor Registry Update –

by Benjamin J. Miller, MD, MS

Since the first 5 sites have started contributing actual patient data to the MsTR, we have been acutely focused on ensuring data accuracy and integrity. It is always a fine balance between ease of data entry and absolute trust in the data we are collecting. Given that our overarching goal is to provide a reliable database that can be used to answer scientific questions about surgical management of sarcoma, our compass will always be aligned to data integrity as the most important factor. Despite a substantial effort to find ways to reliably identify patients treated for a primary bone or soft tissue sarcoma using procedural and diagnostic codes in the medical record, it is now clear that the codes used in sarcoma are unfortunately not accurate enough to reflect our patients of interest with the highest degree of certainty. Ultimately this will

result in a product that is much more likely to be meaningful, but it will require heavy reliance on provider-entered data. This is relevant to the participating centers as the minimal data set cannot simply be fields abstracted from the medical record, but will necessitate the extra effort needed to provide data points so that we can be assured of the appropriateness of each patient's inclusion.

This year has also witnessed several positive developments and continuation of important initiatives. The final “smart-forms” are completed and soon will start to be rolled out to participating institutions that use Epic – this will improve dissemination and decrease the IT support needed at individual institutions. We continue to be active in grant preparation (patient-reported outcomes and assess-

ment in lower extremity bone sarcoma) and grant execution (giant cell tumor RCT). Thanks to all the hard work of the Steering Committee: Data Elements Subcommittee Chair Nate Mesko, Publications Subcommittee Chair Adam Levin, Grants Subcommittee Chair Eric Henderson, and members Megan Anderson, Joe Schwab, Meredith Bartelstein, George Calvert, Shalin Patel, and Kristy Weber.

As always, we encourage all interested surgeons or institutions to join the effort! If any further questions or if you are considering joining the MsTR, please reach out to me or another Steering Committee Member, or explore <https://www.aaos.org/registries/> for additional information and contacts for you and your institutional support team.

# Guidelines and Evidence Based Medicine Committee Update –

by Nicholas Tedesco, DO, Chair

The Guidelines and Evidence-Based Medicine (GEBM) Committee continues to work hard for the MSTs membership. We completed the first ever all-MSTS clinical practice guideline (CPG) on management of metastatic humerus disease using and validating our own novel methodology. It was ratified and accepted by the executive committee in April of 2023. It is now available on the new GEBM section of the MSTs website along with our previous CPG's. Future plans will be to submit the most recent CPG to JAAOS for publication. Please be on the lookout for it in the coming months!

In order to serve the MSTs membership at large, we have developed a series of novel clinical practice assessments. These are aimed at being an objective, evidence for vs. evidence against, literature review of

new and emerging technologies. These are not meant to contain recommendations, but rather complete the assessment of the new technology or idea to help you decide if it will or should change your practice or not, if it's something you feel needs further research, or if you simply want quick education on a topic unfamiliar to you. Because it will be early reviews of newer technology before a substantial amount of data exists, they will be sunset at 1 year when the next series of assessments will come out. The first series have been published on the GEBM link of the MSTs website, with the plan for the next series to be released next year right before the annual meeting. The current topics posted include:

1. 3-D patient specific instrumentation in bone sarcoma

2. The ENLIVEN clinical trial
3. Radiofrequency ablation for skeletal metastases
4. Use of doxycycline in aneurysmal bone cysts
5. Use of radiolucent implants in surgery for musculoskeletal oncology

The GEBM Committee is here to serve the entire MSTs membership! If you have any ideas for clinical practice guidelines, appropriate use criteria, novel clinical practice assessments, or other quality improvement projects, please do not hesitate to reach out to myself or any GEBM committee members. Other current members include: Yee-Cheen Doung, Pietro Ruggieri, Matthew Colman, and Hennock Wolde-Semait.



## Musculoskeletal Tumor Society

1515 E. Woodfield Road, Suite 345 • Schaumburg, IL 60173

website: [www.MSTS.org](http://www.MSTS.org)

phone: 847/698-1625 e-mail: [info@msts.org](mailto:info@msts.org)